Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$3.16M+1.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jonathan E. Dickinson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 163
- Beta
- 0.88
- Country
- FR
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -27.13
Financials
Revenue
$3.16M+1.9%Net Income
$-19.89MEBITDA
$-21.23MFree Cash Flow
$-21.42MEPS (diluted)
$-0.21Shares Outstanding (diluted)
93.83M+428.0%Operating Expenses
$7.47MCash & Debt
$10.89MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.79M | $-49.18M | $-0.53 |
| 2024 | $12.62M | $-49.47M | $-0.61 |
| 2023 | $51.90M | $-7.57M | $-0.09 |
| 2022 | $57.67M | $-58.10M | $-0.73 |
| 2021 | $12.11M | $-52.81M | $-0.57 |
| 2020 | $69.77M | $-63.98M | $-0.01 |
| 2019 | $68.97M | $-20.76M | $-0.31 |
| 2018 | $79.89M | $3.05M | $0.05 |
| 2017 | $32.63M | $-48.38M | $-0.89 |
| 2016 | $56.16M | $12.64M | $0.23 |
| 2015 | $17.91M | $-6.71M | $-0.13 |
| 2014 | $907.0K | $-19.65M | $-0.39 |
| 2013 | $12.47M | $-2.89M | $-0.07 |
| 2012 | $10.38M | $-3.20M | $-0.08 |
Valuation
IPHAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
58+94.44%Social Signal Score
Mentions (8)
- Newszacks.com·22h ago·Positive
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA) Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·12d ago·Positive
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Negative
Innate Pharma Q2 Earnings Call Highlights Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.
View source ↗ - Newsmarketbeat.com·52d ago·Negative
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
View source ↗ - Newsbusinesswire.com·53d ago·Neutral
Innate Pharma Announces Conference Call and Webcast MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
View source ↗ - Newsprnewswire.com·57d ago·Negative
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézar
View source ↗
Earnings
Typical surprise -6.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Sep 17$-0.24 vs $-0.29beat
- Wed, May 13$-0.35 vs $-0.35beat
- Thu, Nov 13$-0.30 vs $-0.33beat
- Tue, May 13$-0.35 vs $-0.27miss
- Wed, Nov 13$-0.34 vs $-0.30miss
- Tue, May 14$-0.13 vs $-0.44beat
Estimates and results for IPHA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in IPHA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.